Articles related to Urology

National Cancer Database data suggest that approximately half of prostate cancer focal therapy use from 2010 to 2023 occurred outside current guideline-supported settings, highlighting persistent gaps between clinical practice and available evidence.

Tranexamic acid was associated with lower rates of major bleeding among patients undergoing urologic surgery in a prespecified POISE-3 trial analysis, while thrombotic event rates remained similar between treatment groups.

Radiation oncology practices report substantial revenue declines following 2026 CMS coding changes, with some centers citing reimbursement reductions of 15% to 30%. Stakeholders warn the financial pressures could affect treatment access, particularly in community and rural settings.

Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.

Researchers identified a metabolic pathway in which amino acid breakdown generates propionyl-CoA, sustaining cholesterol production and androgen signaling in prostate cancer models. The findings suggest a potential mechanism of hormone therapy resistance, though clinical relevance remains unproven.

A Veterans Health Administration analysis of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA level below 0.2 ng/mL within 9 months was associated with improved survival. The retrospective findings support a threshold previously identified in clinical trials.